MEN2501 / Menarini, Insilico Medicine - LARVOL DELTA

ISM9682A, a novel and potent KIF18A inhibitor, shows robust antitumor effects against chromosomally unstable cancers (AACR 2024) - "In addition to its robust biological potency and high selectivity, ISM9682A exhibits favorable drug-like properties, including desirable in vitro ADMET characteristics and excellent in vivo exposure, clearance, as well as good oral bioavailability across multiple preclinical species. Collectively, these findings highlight the potential of ISM9682A as a novel and highly potent KIF18A inhibitor for the treatment of CIN-high cancers."

Breast Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • KIF18A

??MEN2501-01?: A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer (clinicaltrialsregister.eu) - P1 | N=23 | Not yet recruiting | Sponsor: Stemline Therapeutics Inc.

New P1 trial • Oncology • Ovarian Cancer • Solid Tumor

InSilico Medicine…has received approximately HKD39 million from Menarini Group ('Menarini') as an additional milestone payment, following the completion of first-in-patient dosing in a Phase I clinical trial of MEN2501 (HKEXnews)

Financing • First-in-human • Platinum resistant • Trial status • Ovarian Cancer